Nicotine/mecamylamine combination treatment for smoking cessation

Drug Development Research

Volumn 38, Issue 3-4, 1996, Pages 243-256

  Rose, Jed E ^b,c   Westman, Eric C ^a,b   Behm, Frederique M ^b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Apartment No 1307   (United States)

Author keywords

Nicotine; Smoking; Smoking cessation

Indexed keywords

MECAMYLAMINE; NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE;

ABDOMINAL CRAMP; ABSTINENCE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; SUBSTITUTION THERAPY; TRANSDERMAL DRUG ADMINISTRATION; URINE RETENTION;

EID: 0030444590     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2299(199607/08)38:3/4<243::aid-ddr13>3.0.co;2-%23     Document Type: Article

References (59)

1. Allanby KD, Trounce JR (1957): Excretion of mecamylamine after intravenous and oral administration. BMJ 23:1219-1221.
2. American Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
3. Burling TA, Lovett SB, Richter WT, Frederiksen LW (1983): Alveolar carbon monoxide: The relative contributions of daily cigarette rate, cigarette brand, and smoking topography. Addict Behav 8:23-26.
4. Centers for Disease Control (1990): Cigarette smoking among adults - United States, 1990. MMR 41:354-355.
5. Clarke PBS (1991): Nicotinic receptor blockade therapy and smoking cessation. Br J Addiction 86:501-555.
6. Collins AC, Evans CB, Miner LL, Marks MJ (1986): Mecamylamine blockade of nicotine responses: Evidence for two brain nicotinic receptors. Pharmacol Biochem Behav 24:1767-1773.
7. Collins AC, Bhat RV, Pauly JR, Marks MJ (1990): Modulation of nicotine receptors by chronic exposure to nicotinic agonists and antagonists. In Bock G, Marsh J (eds): The Biology of Nicotine Dependence. Chichester: John Wiley & Sons, pp 68-82.
8. Cornish JW, McNicholas LF, O'Brien CP (1995): Treatment of substance-related disorders. In Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press, pp 707-724.
9. Corrigall WA, Coen KM (1989): Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99:473-478.
10. Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, Cheney RA, Hatlelid K, Thompson AB, Rennard SI (1991): Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. Arch Intern Med 151:749-752.
11. Eichelberg D, Stolze P, Block M, Buchkremer G (1989): Contact allergies induced by tts-treatment. Methods Fund Exp Clin Pharmacol 11:223-225.
12. Foulds J, Stapleton J, Feyerabend C, Vesey C, Jarvis M, Russell MAH (1992): Effect of transdermal nicotine patches on cigarette smoking: A double blind crossover study. Psychopharmacology 106:421-427.
13. Gritz E, Marcus A, Carr C (1988): Unaided smoking cessation: Great American smokeout and new year's eve quitters. J Psychosocial Oncol 6:217-234.
14. Hirsch A, Slama K, Alberisio A, Fowler G, Lagrue G, Malvezzi I, Manley M, Molimard R, Tonnesen P (1994): Smoking cessation recommendations: Recommendations for health professionals. Advisory Group of the European School of Oncology. Eur J Cancer 30A:253-263.
15. Hjalmarson A, Franzon M, Westin A, Wiklund O (1994): Effect of nicotine nasal spray on smoking cessation. Arch Intern Med 154:2567-2572.
16. Hughes JR (1995): Combining behavioral therapy and pharmacotherapy for smoking cessation: an update. In Onken LS, Blaine JD, Boren JJ (eds): Integrating Behavior Therapies with Medication in the Treatment of Drug Dependence, NIDA Research Monograph. Washington, DC: US Government Printing Office, pp 92-109.
17. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984): Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology. 83:82-87.
18. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991): Symptoms of tobacco withdrawal: A replication and extension. Arch Gen Psychiatry 48:52-59.
19. Hughes JR, Gulliver SB, Fenwick JW, Valliere WA, Cruser K, Pepper S, Shea P (1992): Smoking cessation among self-quitters. Health Psychol 11:331-334.
20. Jaffe JH (1992): Pharmacological Treatment of Drug Dependence: An Overview. In Cohen-Yanez J, Amezcua-Gastelum L, Villarreal J, Zavala LS (eds): Drug Dependence: From the Molecular to the Social Level. Amsterdam: Elsevier Science Publishers BV, pp 153-167.
21. Jarvik ME (1991): Beneficial effects of nicotine. Br J Addiction 86:571-576.
22. Jarvik ME, Assil KM (1988): Mecamylamine blocks the burning sensation of nicotine on the tongue. Chem. Senses. 13:213-217.
23. Jasinski DR, Henningfield JE (1988): Conceptual basis of replacement therapies for chemical dependence. In Pomerleau OF, Pomerleau CS (eds): Nicotine Replacement: A Critical Evaluation. New York: Alan R. Liss, pp 13-34.
24. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, Hays JT, Lewis SF, Baker TB (1995): Varying nicotine patch dose and type of smoking cessation counseling. JAMA 274:1347-1352.
25. Lando HA (1991): Toward a comprehensive strategy for reducing the health burden of tobacco. In West R, Grunberg NE (eds): Br J Addiction 86:649-652.
26. Levin ED, Rose JE (1991): Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Br Res Bull 27:125-128.
27. Lindstrom J, Anand R, Peng X, Gerzanich V (1995): Neuronal nicotinic structure and function. In Clarke PBS, Quik M, Adlkofer FX, Thurau K (eds): Effects of nicotine on biological systems. II. Basel: Birkhäuser Verlag, pp 45-52.
28. Lukas RJ, Ke L, Bencherit M, Eisenhour CM (1996): Regulation by nicotine of its own receptors. Drug Devel Res 38:136-148.
29. Martin BR, Onaivi ES, Martin TJ (1989): What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 38:3391-3397.
30. Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, Griffiths RR (1986): Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88:420-425.
31. Palmer KJ, Buckley MM, Faulds D (1992): Transdermal nicotine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 44:498-529.
32. Pomerleau OF, Pomerleau CS (1988): Introduction. In Pomerleau OF, Pomerleau CS (eds): Nicotine Replacement: A Critical Evaluation. New York: Alan R. Liss, pp 1-9.
33. Pomerleau CS, Pomerleau OF, Majchrzak MJ (1987): Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology 91:391-393.
34. Raw M, Jarvis MJ, Feyerabend C, Russell MAH (1980): Comparison of nicotine chewing-gum and psychological treatments for dependent smokers. BMJ 281:481-482.
35. Rose JE (1986): Transdermal nicotine as a strategy for nicotine replacement. In Okene JK (ed): The Pharmacologic Treatment of Tobacco Dependence: Proceedings of the World Congress Institute for the Study of Smoking Behavior and Policy, Cambridge, MA, pp 158-166.
36. Rose JE, Levin E (1991): Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacol Biochem Behav 41:219-226.
37. Rose JE, Jarvik ME, Rose KD (1984): Transdermal administration of nicotine. Drug Alcohol Depend 13:209-213.
38. Rose JE, Herskovic JE, Trilling Y, Jarvik ME (1985): Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther 38:450-456.
39. Rose JE, Sampson A, Levin ED, Henningfield JE (1989): Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol Biochem Behav 32:933-938.
40. Rose JE, Levin ED, Behm FM, Adivi C, Schur C (1990): Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther 47:323-330.
41. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Lane JD, Ripka GV (1994a): Combine effects of nicotine and mecamylamine in attenuating smoking satisfaction. Exp Clin Psychopharmacol 2:1-17.
42. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV (1994b): Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86-99.
43. Russell MAH, Feyerabend C (1978): Cigarette smoking: A dependence on high-nicotine boli. Drug Metab Rev 8:29-57.
44. Russell MAH, Raw M, Jarvis MJ (1980): Clinical use of nicotine chewing-gum. BMJ 280:1599-1602.
45. Sachs DPL, Sawe U, Leischow SJ (1993): Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 153:1881-1890.
46. Sachs DPL (1995): Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch Intern Med 155:1-8.
47. Sanders M, D'Amico D, Perkins KA, Wilson AS, Stiller RL, Heesch C, McNamara D (1996): Effects of mecamylamine on human nicotine discrimination. Poster presented at the Second Annual Meeting of the Society for Research on Nicotine and Tobacco, Washington, DC.
48. Shiffman SM, Jarvik ME (1976): Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 50:35-39.
49. Shipley R, Rose J (1992): Quit Smart Stop Smoking Guide. Durham, NC: JB Press.
50. Stolerman IP (1986): Could nicotine antagonists be used in smoking cessation? Br J Addiction 81:47-53.
51. Stolerman IP, Goldfarb T, Fink R, Jarvik ME (1973): Influencing cigarette smoking with nicotine antagonists. Psychopharmacology 28:247-259.
52. Tennant JFS, Tarver AL, Rawson RA (1984): Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. NIDA Res Monog 49:239-246.
53. Tønnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer H, Stockner M (1988): Two and four mg nicotine chewing gum and group counseling in smoking cessation: An open, randomized, controlled trial with a 22 month follow-up. Addiction Behav 13:17-27.
54. Tønnesen P, Nørregard J, Mikkelsen K, Jørgensen S, Nilsson F (1993): A double-blind trial of a nicotine inhaler for smoking cesation. JAMA 269:1268-1271.
55. USDHHS (1988): The Health Consequences of Smoking: Nicotine Addiction. Rockville, MD: Office on Smoking and Health.
56. Westman EC, Behm FM, Rose JE (1996): Airway sensory replace ment as a treatment for smoking cessation. Drug Devel Res 38:257-262.
57. Westman EC, Levin ED, Rose JE (1992): Smoking while wearing the nicotine patch: Is smoking satisfying or harmful? Clin Res 40:871A.
58. Westman EC, Levin ED, Rose JE (1993): The nicotine patch in smoking cessation: A randomized trial with telephone counseling. Arch Intern Med 153:1917-1923.
59. Wonnacott S (1990): Characterization of nicotine receptor sites in the brain. In Wonnacott, Russell MAH, Stolerman IP (eds): Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects. New York: Oxford University Press, pp 226277.